each among R1 and R2 is chosen independently from group comprising hydrogen atom (H), -OH, -OR', -SH, -SR', -SOR', -SO2R', -NO2, -NH2, -NHR', -N(R')2, -NHCOR'. -N-(COR')2, -NHSO2R', (C1-C12)-alkyl, (C1-C12)-halogenalkyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl and substituted or unsubstituted heteroaromatic group; R3 is chosen from group comprising -OH and -OMe wherein group R' or each among groups R' is chosen independently from group comprising -OH, (C1-C12)-alkyl, (C1-C12)-halogenalkyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl, substituted or unsubstituted arylalkenyl and substituted or unsubstituted heteroaromatic group; if group R1 or R2 represents group of the formula -N(R')2 or -N(COR')2 then all groups R' can comprise similar or different values, either groups R' in common with nitrogen atom to which they are added can form 5-7-membered heterocyclic ring. Aryl group or aryl moiety of aralkyl and arylalkenyl group represents a carbocyclic aryl group comprising 6 carbon atoms in carbocyclic ring; aralkyl group represents (C1-C6)-alkyl group substituted with abovementioned aryl group; arylalkenyl group represents (C2-C6)-alkenyl group substituted with abovementioned aryl group; heteroaromatic group represents a heterocyclic aromatic group comprising from 5 to 7 atoms in ring wherein heteroatoms in ring are chosen from nitrogen atom; substituted in aryl and heteroaromatic groups and in aryl moiety of aralkyl and arylalkenyl groups are chosen from group comprising (C1-C12)-alkyl, (C1-C12)-halogenalkyl, (C1-C12)-alkoxy-, (C1-C12)-alkylthio-group, -NH2, (C1-C6)-alkylamino-, di-(C1-C6)-alkyl)-amino-, (C1-C4)-alkanoylamino-, di-(C1-C4)-alkanoylamino-group, -NO2, -CN and halogen atom, its derivatives wherein nitrogen atom is quaternized. Proposed compounds possess anti-tumor activity and can be used in treatment or prophylaxis of cancerous diseases, for example, ovary cancer, prostate cancer, mammary cancer and melanoma.;EFFECT: valuable medicinal properties of compounds and pharmaceutical composition, improved methods of treatment, improved methods of synthesis.;38 cl, 10 sch, 2 tbl, 25 ex"/> DERIVATIVES OF VARIOLINE, METHODS FOR THEIR PREPARING (VARIANTS), INTERMEDIATE COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR TREATMENT (VARIANTS)
首页> 外国专利> DERIVATIVES OF VARIOLINE, METHODS FOR THEIR PREPARING (VARIANTS), INTERMEDIATE COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR TREATMENT (VARIANTS)

DERIVATIVES OF VARIOLINE, METHODS FOR THEIR PREPARING (VARIANTS), INTERMEDIATE COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR TREATMENT (VARIANTS)

机译:变异体的衍生物,其制备方法(变异体),中间化合物,药物成分和治疗方法(变异体)

摘要

FIELD: organic chemistry, chemical technology, medicine, pharmacy.;SUBSTANCE: invention relates to novel derivatives of varioline and their pharmaceutically acceptable salts and esters possessing anti-tumor activity. In compound of the formula (I): each among R1 and R2 is chosen independently from group comprising hydrogen atom (H), -OH, -OR', -SH, -SR', -SOR', -SO2R', -NO2, -NH2, -NHR', -N(R')2, -NHCOR'. -N-(COR')2, -NHSO2R', (C1-C12)-alkyl, (C1-C12)-halogenalkyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl and substituted or unsubstituted heteroaromatic group; R3 is chosen from group comprising -OH and -OMe wherein group R' or each among groups R' is chosen independently from group comprising -OH, (C1-C12)-alkyl, (C1-C12)-halogenalkyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl, substituted or unsubstituted arylalkenyl and substituted or unsubstituted heteroaromatic group; if group R1 or R2 represents group of the formula -N(R')2 or -N(COR')2 then all groups R' can comprise similar or different values, either groups R' in common with nitrogen atom to which they are added can form 5-7-membered heterocyclic ring. Aryl group or aryl moiety of aralkyl and arylalkenyl group represents a carbocyclic aryl group comprising 6 carbon atoms in carbocyclic ring; aralkyl group represents (C1-C6)-alkyl group substituted with abovementioned aryl group; arylalkenyl group represents (C2-C6)-alkenyl group substituted with abovementioned aryl group; heteroaromatic group represents a heterocyclic aromatic group comprising from 5 to 7 atoms in ring wherein heteroatoms in ring are chosen from nitrogen atom; substituted in aryl and heteroaromatic groups and in aryl moiety of aralkyl and arylalkenyl groups are chosen from group comprising (C1-C12)-alkyl, (C1-C12)-halogenalkyl, (C1-C12)-alkoxy-, (C1-C12)-alkylthio-group, -NH2, (C1-C6)-alkylamino-, di-(C1-C6)-alkyl)-amino-, (C1-C4)-alkanoylamino-, di-(C1-C4)-alkanoylamino-group, -NO2, -CN and halogen atom, its derivatives wherein nitrogen atom is quaternized. Proposed compounds possess anti-tumor activity and can be used in treatment or prophylaxis of cancerous diseases, for example, ovary cancer, prostate cancer, mammary cancer and melanoma.;EFFECT: valuable medicinal properties of compounds and pharmaceutical composition, improved methods of treatment, improved methods of synthesis.;38 cl, 10 sch, 2 tbl, 25 ex
机译:技术领域本发明涉及新型的缬氨酸(Varioline)衍生物及其具有抗肿瘤活性的药学上可接受的盐和酯。在公式(I)的化合物中:<图像文件=“ 00000002.GIF” he =“ 66” imgContent =“ undefined” imgFormat =“ GIF” wi =“ 35” />分别位于R 1 和R 2 独立地选自氢原子(H),-OH,-OR',-SH,-SR',-SOR',-SO 2 R',-NO 2 ,-NH 2 ,-NHR',-N(R') 2 ,-NHCOR'。 -N-(COR') 2 ,-NHSO 2 R',(C 1 -C 12 ) -烷基,(C 1 -C 12 )-卤代烷基,取代或未取代的芳基,取代或未取代的芳烷基以及取代或未取代的杂芳族基团; R 3 选自-OH和-OMe,其中R'或R'中的每一个独立地选自-OH,(C 1 -C 12 )-烷基,(C 1 -C 12 )-卤代烷基,取代或未取代的芳基,取代或未取代的芳烷基,取代或未取代的芳基烯基取代或未取代的杂芳族基团;如果组R 1 或R 2 表示公式-N(R') 2 或-N(COR') 2 ,那么所有基团R'可以具有相似或不同的值,与它们所加成的氮原子相同的基团R'可以形成5-7元杂环。芳烷基和芳基烯基的芳基或芳基部分表示在碳环中包含6个碳原子的碳环芳基;芳烷基表示被上述芳基取代的(C 1 -C 6 )-烷基。芳基烯基表示被上述芳基取代的(C 2 -C 6 )-烯基;杂芳族基团表示环中包含5至7个原子的杂环芳族基团,其中环中的杂原子选自氮原子;在芳烷基和杂芳族基团以及芳烷基和芳基烯基的芳基部分中取代的取代基选自(C 1 -C 12 )-烷基,(C 1 -C 12 )-卤代烷基,(C 1 -C 12 )-烷氧基-,(C 1 < / Sub> -C 12 )-烷硫基,-NH 2 ,(C 1 -C 6 )-烷基氨基-,二-(C 1 -C 6 )-烷基)-氨基-,(C 1 -C 4 )-烷酰基氨基-,二-(C 1 -C 4 )-烷酰基氨基-,-NO 2 ,- CN和卤素原子,其衍生物,其中氮原子被季铵化。拟议的化合物具有抗肿瘤活性,可用于治疗或预防卵巢癌,前列腺癌,乳癌和黑色素瘤等癌症疾病;作用:化合物和药物组合物的宝贵药用特性,改进的治疗方法,改进的合成方法;; 38 cl,10 sch,2 tbl,25 ex

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号